Hormonal therapy of pancreatic carcinoma. Rationale and perspectives.
Exocrine pancreas carcinoma is still diagnosed at a relatively late stage, so that only a few cases can be cured by surgery. Therefore, it is desirable that an effective medical therapy be found first to stall the development of the disease and second to improve the life conditions of patients. On the basis of recent discoveries, a new therapeutic approach seems to derive from hormone manipulation. The growth of pancreatic carcinoma appears to be stimulated by various factors, such as Epidermal Growth Factor (EGF) and Insulin-like Growth Factor I (IGF-I), and by various hormones, such as androgens and cholecystokinin. Several studies performed on cell lines and on animal models of pancreatic carcinoma demonstrated an antitumoral effect of certain antihormones and of somatostatin. Taking such studies as a premise, the first clinical studies were finally started in patients suffering from nonoperable pancreatic cancer. Results are still partial and contradictory, but such research is certainly worthy of further study along the lines already taken.
Perilli
D
D
Dipartimento di Medicina Interna, Università di Genova, Italy.
Mansi
C
C
Savarino
V
V
Celle
G
G
D000818:Animals; D005768:Gastrointestinal Hormones / Q000502:physiology; D012739:Gonadal Steroid Hormones / Q000502:physiology; D006133:Growth Substances / Q000502:physiology; D006727:Hormone Antagonists / Q000627:therapeutic use*; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000209:etiology; D013004:Somatostatin / Q000627:therapeutic use*
D005768:Gastrointestinal Hormones; D012739:Gonadal Steroid Hormones; D006133:Growth Substances; D006727:Hormone Antagonists; D013004:Somatostatin